Back to top

Tale of the Tape

Novo Nordisk A/S ’s (NVO - Analyst Report) share price has entered into oversold territory with an RSI value of 21.9. The Zacks Consensus Estimate for Novo Nordisk for the full year period has improved 75 cents over the past two months to $1.90 per share. Currently, Novo Nordisk has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on (NVO - Analyst Report) after its recent drop.

Please login to or register to post a comment.